Glucowise 20mg Tablet contains Teneligliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By selectively inhibiting the DPP-4 enzyme, Teneligliptin enhances the levels of incretin hormones, which in turn increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. Glucowise is prescribed as an adjunct to diet and exercise to improve glycemic parameters in adult patients inadequately controlled on monotherapy or combination therapy. The 20mg dosage provides effective once-daily administration, promoting patient adherence. Clinical studies have demonstrated that Teneligliptin effectively reduces fasting plasma glucose and HbA1c levels with a favorable safety profile and minimal risk of hypoglycemia when used appropriately. It is contraindicated in patients with known hypersensitivity to Teneligliptin or any excipients. Caution is advised in patients with renal or hepatic impairment, and dose adjustments may be necessary based on clinical evaluation. Glucowise should be used under medical supervision, with regular monitoring of blood glucose and renal function to optimize therapeutic outcomes and minimize adverse effects. It is not intended for use in type 1 diabetes or diabetic ketoacidosis.